

**Original research**

**Prediabetic Levels of Hyperglycemia as a Predictor of Microvascular Angina with Possible Involvement of Low Levels of High-Density Lipoprotein Cholesterol and Hemoglobin**

Satoru Suzuki, MD, PhD <sup>1,2,#</sup>, Kenshi Yamanaga, MD, PhD <sup>1,#</sup>, Masanobu Ishii, MD, PhD <sup>1,#</sup>, Erika Matsumoto, BS <sup>3</sup>, Naoto Kuyama, MD, PhD<sup>1</sup>, Kyoko Hirakawa, MD, PhD<sup>1</sup>, Noriaki Tabata, MD, PhD<sup>1</sup>, Tomonori Akasaka, MD, PhD<sup>1</sup>, Koichiro Fujisue, MD, PhD<sup>1</sup>, Shinsuke Hanatani, MD, PhD<sup>1</sup>, Yuichiro Arima, MD, PhD<sup>1</sup>, Hiroki Usuku, MD, PhD<sup>1</sup>, Eiichiro Yamamoto, MD, PhD<sup>1</sup>, Kentaro Oniki, PhD<sup>3</sup>, Hirofumi Soejima, MD, PhD<sup>1</sup>, Junji Saruwatari, PhD<sup>3</sup>, Hiroaki Kawano, MD, PhD<sup>1</sup>, Hideaki Jinnouchi, MD, PhD<sup>4</sup>, Koichi Kaikita, MD, PhD<sup>1,5</sup>, Hirofumi Yasue, MD, PhD<sup>6</sup>, Hisao Ogawa, MD, PhD<sup>7</sup>, Kenichi Tsujita, MD, PhD<sup>1,\*</sup>

<sup>1</sup> Department of Cardiovascular Medicine and Center for Metabolic Regulation of Healthy Aging, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto City 860-8556, Japan;

<sup>2</sup> Department of Cardiovascular Medicine, National Hospital Organization Kumamotominami National Hospital, 2338 Toyofuku, Matsubase-machi, Uki City, Kumamoto Prefecture 869-0593, Japan;

<sup>3</sup> Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto City, 862-0973, Japan;

<sup>4</sup> Diabetes Center, Jinnouchi Hospital, 6-2-3 Kuhonji, Chuo-ku, Kumamoto City 862-0976, Japan;

<sup>5</sup> Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki City 889-1692, Japan;

<sup>6</sup> Division of Cardiovascular Medicine, Kumamoto Kinoh Hospital, Kumamoto Aging Research Institute, 6-8-1 Yamamuro, Kita-ku, Kumamoto City 860-8518, Japan;

<sup>7</sup> Kumamoto University, 2-39-1 Kurokami, Chuo-ku, Kumamoto City 860-8555, Japan.

# Satoru Suzuki, Kenshi Yamanaga, and Masanobu Ishii contributed equally to this article.

1 \*Corresponding author information: Kenichi Tsujita, MD, PhD, Department of  
2 Cardiovascular Medicine and Center for Metabolic Regulation of Healthy Aging, Graduate  
3 School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto City  
4 860-8556, Japan. Phone: +81-96-373-5175, Fax: +81-96-362-3256, E-mail:  
5 tsujita@kumamoto-u.ac.jp

6

7 Total word count: 2833 words in the text, and 293 words in the abstract

8 Total number of figures and tables: 1 figure and 7 tables

1 **Abstract**

2 **Background:** The management of modifiable risk factors, including conventional risk factors,  
3 can play an important role in the treatment for microvascular angina (MVA). The purpose of  
4 this study was to clarify the clinical characteristics of MVA in a case-control study, thereby  
5 elucidating the pathogenesis and management of MVA.

6 **Methods:** This study enrolled 92 consecutive patients with MVA (39 men, 53 women, mean  
7 age 63.2 ±12.1 years) without obstructive coronary artery disease (≥50% stenosis) or  
8 acetylcholine-provoked epicardial coronary spasms between 1993 and 2015. This study  
9 enrolled 691 age-matched Japanese participants (466 men, 225 women, mean age 62.9 ±11.0  
10 years) without a history of chest pain or cardiovascular diseases between 2006 and 2012 as  
11 controls.

12 **Results:** In multivariate logistic regression analysis, elevated haemoglobin A1c (HbA1c) (per  
13 1 mmol/mol), low high-density lipoprotein cholesterol (HDL-C) (per 1mmol/L), and low  
14 haemoglobin (Hgb) (per 10×g/L) levels were significantly associated with MVA (odds ratio  
15 [OR] 1.07[1.04-1.10], p <0.001; OR 0.13[0.06-0.29], p <0.001; OR 0.56[0.44-0.72], p <0.001,  
16 respectively). However, the difference between the prevalence of diabetes in MVA patients vs.  
17 the prevalence in controls was not significant. MVA patients without diabetes had significantly  
18 higher HbA1c levels than control patients without diabetes (39±4 mmol/mol vs. 34±3  
19 mmol/mol, respectively; p <0.001). These results were also true for patients and controls

1 stratified by sex. A higher prevalence of proteinuria and lower mean corpuscular volume of  
2 erythrocytes were found in MVA patients than in controls stratified by sex.

3 **Conclusions:** Hyperglycaemia reflected by mildly elevated HbA1c levels, (i.e., prediabetes)  
4 may be a risk factor for MVA. Low levels of HDL-C and Hgb may also be risk factors for  
5 MVA. MVA could be one of the systemic manifestations of microvascular diseases. The  
6 study may aid in identifying high-risk MVA patients, allowing increased monitoring and  
7 treatments for them.

8  
9  
10 **Section head:** Coronary artery disease

11  
12  
13 **Key words:** Microvascular angina, Coronary microvascular dysfunction, Glycated  
14 Haemoglobin, High-density lipoprotein cholesterol, Haemoglobin

15  
16  
17 **Research checklist:** STROBE checklist: case-control studies

1 **What is already known on this topic:**

2 Microvascular angina (MVA) has been attracting attention of clinical research because MVA can  
3 be associated with future cardiovascular events. The management of modifiable risk factors,  
4 including conventional risk factors, can play an important role in the treatment of MVA because  
5 there is currently no specific treatment of MVA. The purpose of this study was to clarify the  
6 clinical characteristics of MVA.

7

8 **What this study adds:**

9 Hyperglycaemia reflected by mildly elevated haemoglobin A1c levels, (i.e., prediabetes) may be  
10 a risk factor for MVA. Low levels of high-density lipoprotein cholesterol and haemoglobin  
11 may also be risk factors for MVA. A higher prevalence of proteinuria and lower mean  
12 corpuscular volume of erythrocytes were found in MVA patients than in controls stratified by  
13 sex.

14

15 **How this study might affect research, practice or policy:**

16 MVA could be one of the systemic manifestations of microvascular diseases. The study  
17 findings may aid in identifying high-risk patients with MVA, allowing increased monitoring and  
18 treatments for them.

## 1 **Introduction**

2 Patients with suspected angina are frequently found to have non-obstructive coronary  
3 artery disease (CAD). This condition has recently been called “ischaemia with  
4 non-obstructive CAD (INOCA)”<sup>1-5</sup>. Non-acetylcholine (ACh)-provoked epicardial coronary  
5 spasm is sometimes seen in patients with INOCA. A possible cause of this can be  
6 microvascular angina (MVA) due to coronary microvascular dysfunction (CMD). MVA has  
7 been a recent focus of clinical research because MVA has emerged as an important factor  
8 associated with adverse cardiovascular outcomes<sup>1 2 6 7</sup>. However, the pathogenesis and  
9 management of MVA remain unknown.

10 Previous studies have found that ageing, smoking, hypertension (HT), diabetes mellitus  
11 (DM), and dyslipidaemia (DLP) could be associated with MVA<sup>8-10</sup>. In contrast, other studies  
12 have found that DM was uncommon in patients with angina and non-obstructive CAD,  
13 whereas HT and DLP were relatively common<sup>11 12</sup>. Thus, the association between  
14 conventional cardiovascular risk factors and MVA has not yet been established<sup>4</sup>. The  
15 management of modifiable risk factors including conventional risk factors can play an  
16 important role in the treatment of MVA, because there is currently no specific treatment of  
17 MVA<sup>4 13</sup>.

18 The purpose of this study was to clarify the clinical characteristics of MVA in a  
19 case-control study, thereby elucidating the pathogenesis and management of MVA.

## 1 **Methods**

### 2 *Study patients and definition of MVA*

3 We retrospectively enrolled 92 consecutive Japanese patients with MVA (39 men, 53  
4 women) who were admitted to our institution for coronary angiography because of anginal  
5 chest pain between January 1993 and December 2015 (figure 1). All vasoactive drugs,  
6 including calcium channel blockers, nitrates, nicorandil, alpha-adrenergic blockers, and  
7 beta-adrenergic blockers were discontinued  $\geq 48$  hours before coronary angiography (CAG),  
8 which included an ACh provocation test and a coronary flow reserve (CFR) measurement by  
9 intravenous infusion of adenosine triphosphate (ATP). Every study patient underwent CAG  
10 in the morning while fasting. After the ACh provocation test, isosorbide dinitrate (ISDN)  
11 was infused into the left and right coronary arteries, followed by examining the epicardial  
12 coronary artery for stenosis.

13 The diagnosis of MVA was based on satisfying all the criteria for MVA proposed by the  
14 *Coronary Vasomotion Disorders International Study Group* (COVADIS), as follows: (1) signs  
15 and/or symptoms of myocardial ischaemia, (2) absence of obstructive CAD ( $\geq 50\%$  stenosis)  
16 by CAG, (3) objective evidence of myocardial ischaemia (i.e., chest pain and ischaemia on  
17 ECG) with non-epicardial coronary spasm by an ACh-provocation test, and (4) evidence of  
18 impaired coronary microvascular function (CFR  $< 2.0$  by invasive measurement or  
19 non-epicardial coronary spasm during an ACh-provocation test)<sup>14</sup>.

1 Study exclusion criteria were as follows: decompensated heart failure, cardiomyopathy,  
2 severe valvular heart disease, a previous history of coronary artery revascularization, and  
3 obstructive CAD ( $\geq 50\%$  stenosis). Patients were also excluded for a diagnosis of epicardial  
4 coronary spasm that was based on JCS/CVIT/JCC 2023 Guideline Focussed Update on  
5 Diagnosis and Treatment of Vasospastic Angina (Coronary Spastic Angina) and Coronary  
6 Microvascular Dysfunction by the Japanese Circulation Society <sup>1</sup>. In addition, patients were  
7 excluded for other factors as follows: receiving haemodialysis; or having advanced chronic  
8 obstructive pulmonary disease, advanced collagen disease, active inflammatory disease, severe  
9 liver dysfunction, and/or neoplasms at the time of enrolment.

10 The control patients included 691 age-matched Japanese participants (466 men, 225  
11 women) without a history of chest pain or cardiovascular diseases who underwent medical  
12 examinations at the Japanese Red Cross Kumamoto Health Care Centre between January 2006  
13 and April 2012.

14

#### 15 *Measurement of coronary flow reserve*

16 Before the ACh provocation test, we inserted a 0.014-inch guidewire that was equipped  
17 with a Doppler velocity probe (FloWire; Philips Volcano, San Diego, CA) into the left anterior  
18 descending coronary artery. After the ACh provocation test was followed by the  
19 administration of intracoronary ISDN, ATP (150  $\mu\text{g}/\text{kg}/\text{min}$ ) was administered via the central



1 vein until maximal hyperaemia was achieved to allow the calculation of haemodynamic  
2 parameters. When maximal coronary hyperaemia was attained, the FloWire was used to  
3 measure the CFR, as previously described <sup>15</sup>.

4

#### 5 *Definition of risk factors for cardiovascular diseases*

6 The conventional risk factors for cardiovascular diseases were defined as follows:  
7 current smoking, HT (blood pressure  $\geq 140/90$  mmHg or taking anti-hypertensive drugs), DLP  
8 (low-density lipoprotein cholesterol [LDL-C]  $\geq 3.6$  mmol/L [140 mg/dL], high-density  
9 lipoprotein cholesterol [HDL-C]  $< 1.0$  mmol/L [40 mg/dL], triglycerides [TG]  $\geq 1.7$  mmol/L  
10 [150 mg/dL] or taking lipid-lowering drugs), and DM (fasting plasma glucose levels  $\geq 7.0$   
11 mmol/L [126 mg/dL],  $> 11.1$  mmol/L [200 mg/dL] during a 75-g oral glucose tolerance test, or  
12 taking anti-diabetic drugs). In regard to serum glycosylated haemoglobin A1c (HbA1c)  
13 levels, until the end of March 2012, the measurements proposed by the Japan Diabetes Society  
14 (JDS) were applied for study patients; whereas starting in April 2012, the measurements  
15 described by the National Glycohemoglobin Standardisation Programme (NGSP) were  
16 adopted. In our study, the HbA1c levels (JDS) measured until March 2012 were adjusted to  
17 the NGSP levels (i.e.,  $\text{HbA1c [NGSP] [\%]} = \text{HbA1c [JDS] [\%]} + 0.4$ ) <sup>16</sup>. Additionally, the  
18 HbA1c levels (NGSP) (%) were adjusted to the HbA1c levels (IFCC) (mmol/mol) (i.e.,  
19  $\text{HbA1c [IFCC] [mmol/mol]} = 10.93 \times \text{HbA1c [NGSP] (\%)} - 23.52$ ).

1

2 *Patient and public involvement*

3 Patients and/or the public were not involved in the design, or conduct, or reporting, or  
4 dissemination plans of this research. We plan to disseminate the findings to participants and  
5 the public.

6

7 *Statistical analysis*

8 Continuous values were expressed as means  $\pm$  standard deviation (SD), whereas data  
9 with a skewed distribution were expressed as medians (interquartile range). Continuous  
10 variables were compared by two-tailed unpaired t-tests. A Mann-Whitney U test was  
11 performed for continuous variables with a skewed distribution. Frequencies of clinical  
12 variables stratified into two groups were compared by the Fisher exact test.

13 Clinical parameters were assessed by univariate and multivariate logistic regression  
14 analyses for significant association with MVA. The multivariate logistic regression analysis  
15 was used to evaluate parameters that were identified as statistically significant ( $p < 0.05$ ) by  
16 univariate logistic regression analysis, with the exclusion of redundant and/or missing data on  
17 the variables. We did not include 'DLP' in the multivariate logistic regression analysis  
18 because the correlation between 'DLP' and HDL-C levels was strong. The variables 'current  
19 smoking' and 'proteinuria' were not included in the multivariate logistic regression analysis

1 because there were only a few patients who were current smokers or had proteinuria ([tables](#)

2 [3-5](#)).

3 Stata version 18 (Stata Corp., College Station, TX, USA) and BellCurve for Excel,

4 version 4.06 (Social Survey Research Information Co., Ltd., Tokyo, Japan) were used for

5 statistical analysis. Statistical significance was defined as a p-value < 0.05.

## 1 **Results**

### 2 *Clinical characteristics*

3 [Table 1](#) shows the clinical characteristics of 92 (39 men, 53 women) patients with MVA  
4 and 691 (466 men, 225 women) control participants. The patients with MVA had a  
5 significantly lower prevalence of DLP; higher HbA1c, lower HDL-C, higher CRP, and lower  
6 Hgb levels; and a higher prevalence of proteinuria than the control participants.

7 [Table 2](#) shows the clinical characteristics of MVA patients and control participants  
8 stratified by sex. The men patients with MVA had significantly higher HbA1c, lower HDL-C,  
9 and lower Hgb levels; and a higher prevalence of proteinuria than the control participants.  
10 The women patients with MVA had significantly higher HbA1c, lower HDL-C, higher TG,  
11 higher CRP, higher WBC, and lower Hgb levels; and higher prevalence of current smoking,  
12 and higher prevalence of proteinuria than the control participants.

13

### 14 *Univariate and multivariate logistic regression analysis of characteristics associated with*

### 15 *MVA*

16 [Table 3](#) shows the results of univariate and multivariate logistic regression analysis for  
17 the association of variables with MVA. Univariate logistic regression analysis showed that  
18 women, HT, DLP, HbA1c, HDL-C, Hgb, and proteinuria were all significantly associated with  
19 MVA. Multivariate logistic regression analysis showed that HbA1c, HDL-C, and Hgb were

1 significantly associated with MVA.

2 [Table 4](#) shows the results of univariate and multivariate logistic regression analysis for  
3 MVA in men. Univariate logistic regression analysis showed that HbA1c, HDL-C, Hgb, and  
4 proteinuria were all significantly associated with MVA. Multivariate logistic regression  
5 analysis showed that HbA1c, HDL-C, and Hgb were significantly associated with MVA.

6 [Table 5](#) shows the results of univariate and multivariate logistic regression analysis for  
7 MVA in women. Univariate logistic regression analysis showed that current smoking,  
8 HbA1c, HDL-C, CRP, WBC, Hgb, and proteinuria were all significantly associated with MVA.  
9 Multivariate logistic regression analysis showed that HbA1c, HDL-C, WBC, and Hgb were  
10 significantly associated with MVA.

11

12 *Erythrocyte indices of MVA in men and women*

13 [Table 6](#) compares the erythrocyte indices between patients with MVA and control  
14 participants stratified by sex. Men with MVA had a significantly lower Hgb level and lower  
15 mean corpuscular volume (MCV) than the control men. Women with MVA had a  
16 significantly lower Hgb level, lower MCV, and a lower serum iron level than the control  
17 women.

18

19 *Clinical characteristics of patients with MVA stratified by CFR <2.0 and CFR ≥2.0*

1            [Table 7](#) shows the clinical characteristics of CFR  $<2.0$  and CFR  $\geq 2.0$  in 55 MVA  
2 patients whose CFRs were measured amongst 92 MVA patients. CFR  $\geq 2.0$  was more  
3 common in women with MVA than in men with MVA (29/35 [83%] vs. 9/20 [45%],  $p = 0.006$ ).

## 1 Discussion

2 This case-control study investigated the clinical characteristics of patients with MVA.  
3 The major findings were as follows: (1) amongst 92 MVA patients, 39 were men (42%) and 53  
4 were women (58%) (table 1 and figure 1); (2) elevated HbA1c, low HDL-C, and low Hgb  
5 levels were significantly associated with MVA in men and women (tables 4-5); (3) proteinuria  
6 was more common in men and women patients with MVA than in the control men and women,  
7 respectively (table 2); (4) MCV was significantly lower in men and women patients with MVA  
8 than in the control men and women, respectively (table 6); (5) in patients with MVA, a CFR  
9  $\geq 2.0$  was more common in women than in men (table 7). To the best of our knowledge, this  
10 study is the first to report that elevated HbA1c, low HDL-C, and low Hgb levels were  
11 significantly associated with MVA, and a CFR  $\geq 2.0$  was more common in women with MVA  
12 than in men with MVA.

13 The mechanisms of CMD, which is the cause of MVA, are multifactorial and result from  
14 functional or structural abnormalities in the coronary microvasculature, including (1)  
15 increased vasoconstriction, (2) impaired coronary vasodilator capacities, and (3) increased  
16 coronary microvascular resistance, all three of which can occur alone or in combination<sup>1</sup>. In  
17 this study, we enrolled 92 consecutive Japanese patients with MVA who underwent  
18 comprehensive evaluation of coronary microvascular function that consisted of cardiac  
19 catheterisation with an ACh provocation test and CFR measurements (interventional

1 diagnostic procedure) to assess CMD. We evaluated the clinical characteristics of the MVA  
2 patients.

3 This study showed that an elevated HbA1c level was significantly associated with MVA.  
4 This result was true for both men and women (tables 3-5). The mean HbA1c levels in MVA  
5 patients were  $44\pm 11$  mmol/mol,  $43\pm 11$  mmol/mol, and  $44\pm 11$  mmol/mol in men+women, men,  
6 and women, respectively, which are not severely hyperglycaemic levels (tables 1-2). Some  
7 reports have shown that diabetic microvascular diseases, such as retinopathy or nephropathy,  
8 can precede the appearance of type 2 diabetes, and may contribute to the development of  
9 micro-/macro-vascular complications in patients with type 2 DM, prediabetes, or  
10 hyperglycaemia<sup>17 18</sup>. Another study has shown that proteinuria in prediabetes might be an  
11 early biomarker for detectable diabetic nephropathy<sup>19</sup>. This study found no differences of  
12 the prevalence rates of DM between the patients with MVA and the control participants.  
13 However, in this study, the number of proteinuria was significantly higher in patients with  
14 MVA than in the control participants. The HbA1c levels excluding DM patients were  
15 significantly higher in patients with MVA than in the control participants. (tables 1-2). These  
16 findings suggested that hyperglycaemia reflected by mildly elevated HbA1c levels such as in  
17 patients with prediabetes could be critically involved in the development of MVA.  
18 Hyperglycaemia may contribute to microvascular diseases by the suppression of  
19 endothelium-dependant vasodilation through the increased production of free radicals<sup>13</sup>.



1 Therefore, microvascular diseases associated with hyperglycaemia, as reflected by mildly  
2 elevated HbA1c levels (i.e., prediabetes), could represent systemic phenomena that extend  
3 beyond pathologic manifestations such as nephropathy to the coronary circulation. Mildly  
4 elevated HbA1c levels could be a critical marker for MVA.

5 This study showed that a low Hgb level was significantly associated with MVA. This  
6 result was true for both men and women ([tables 3-5](#)). A previous paper reported that reduced  
7 haemoglobin could predict adverse outcomes in patients with ischaemic heart disease not only  
8 through reduced oxygen delivery but also through reduced nitric oxide availability<sup>20</sup>. In this  
9 study, although the Hgb levels did not satisfy the criterion for anaemia, Hgb and MCV levels  
10 were significantly lower in patients with MVA than in control participants, in both men and  
11 women ([table 6](#)). The serum iron level was significantly lower in the MVA women patients  
12 than in the control women. By contrast, the difference between the ferritin levels in MVA  
13 women patients and control women was not significant. Based on these observations,  
14 haematopoietic dysfunction caused by an iron disorder could be associated with MVA,  
15 although the aetiology could not be clarified by the available data in this study.

16 This study found that a low HDL-C level was significantly associated with MVA in both  
17 men and women ([tables 4-5](#)). Low HDL-C is an established risk factor not only for  
18 macrovascular events, but also for microvascular diseases in diabetic patients<sup>21</sup>. The  
19 underlying mechanisms involved in the macrovascular and microvascular diseases in diabetes

1 have been found to be the association of low HDL-C levels with increased oxidative stress,  
2 increased inflammation, and dysfunctional endothelium <sup>22</sup>. Another study has shown that  
3 HDL-C could be a factor involved in reduced CFR <sup>8</sup>. Based on these findings altogether, low  
4 HDL-C could be associated with MVA.

5 In this study, of 55 patients with MVA who underwent CFR measurement, a CFR  $\geq 2.0$   
6 was more common in women than in men (29 women with CFR  $\geq 2.0$  [29/35 =83%] vs. 9  
7 women with CFR  $< 2.0$  [9/20 =45%],  $p = 0.006$ ) (table 7). MVA patients with a CFR  $\geq 2.0$  had  
8 ischaemic findings during anginal symptoms and on ECG without epicardial coronary spasms  
9 by the ACh provocation test. The results suggested that these patients might have coronary  
10 microvascular spasms, although coronary microvascular spasms cannot be directly visualised.  
11 Our finding that coronary microvascular spasm was more common in women than in men was  
12 consistent with the findings of previous studies <sup>23 24</sup>. In our study, the women with MVA and  
13 a CFR  $\geq 2.0$  were aged  $62.5 \pm 11.4$  years (data not shown), which suggested that many of them  
14 were postmenopausal and had oestrogen deficiency. Oestrogen can modulate coronary  
15 microvascular vasomotor function <sup>13</sup>. There are several types of MVA, which include  
16 increased vasoconstriction (microvascular spasm), impaired vasodilator capacity, and  
17 increased resistance <sup>1</sup>. The different types of MVA might be sex specific. Further studies  
18 on the association of MVA subtypes with the sex of study patients are needed.

19 MVA can be detected in 30% to 50% of patients with anginal symptoms and

1 nonobstructive CAD on invasive CAG <sup>5 14</sup>. CMD leading to MVA can play an important role  
2 not only in angina, but also in various cardiovascular diseases such as acute coronary  
3 syndrome and left ventricular hypertrophy <sup>13 25</sup>. Patients with anginal symptoms and  
4 angiographically nonobstructive CAD currently have large burdens of cardiovascular disease,  
5 including repeated hospitalisations and CAG, which also indicate that the economic burden of  
6 MVA is increasing <sup>26</sup>. The majority of MVA patients remain undertreated because of the lack  
7 of evidence-based data. This study showed that hyperglycaemia as reflected by mildly  
8 elevated HbA1c levels, and low HDL-C and Hgb levels were significantly associated with  
9 MVA, and that a CFR  $\geq 2.0$  was more common in women than in men patients with MVA.  
10 Because there is currently no specific treatment for MVA, the management of modifiable risk  
11 factors, including conventional risk factors, can play an important role in the treatment of  
12 MVA <sup>4 13</sup>. Therefore, our observational findings may be helpful for further risk stratification  
13 and the development of treatment strategies for MVA.

14

#### 15 *Study Limitations*

16 This study has several limitations. First, it was a single-centre study with a relatively  
17 small sample size. Second, it was a retrospective study. Third, the study only included  
18 Japanese patients and participants. Fourth, our results may not be applicable to patients who  
19 are outside of the age range we studied. Fifth, the control group comprised 691 age-matched

1 Japanese participants (466 men, 225 women) without a history of either chest pain or  
2 cardiovascular diseases. We did not have any information on the medications taken by the  
3 control participants. Moreover, we could not completely rule out that a control participant  
4 might have asymptomatic CAD. Sixth, we did not measure CFR in all the study patients and  
5 all the control participants. Further analyses and recalibrations of a larger and independent  
6 study population are needed.

1    **Conclusions**

2            Hyperglycaemia reflected by mildly elevated HbA1c levels, (i.e., prediabetes) may be a  
3 risk factor for MVA. Low HDL-C and low Hgb levels may also be risk factors for MVA.  
4 CFR  $\geq 2.0$  was more common in women than in men amongst MVA patients. MVA could be  
5 a systemic phenomenon associated with microvascular diseases. The study findings may aid  
6 in identifying high-risk patients with MVA, allowing increased monitoring and treatments for  
7 them.

1 **Contributions**

2 SS, KY, MI, HY, HO, and KT designed the study. SS, KY, MI, EM, NK, KH, NT, TA, KF,  
3 SH, KO, JS, and KT collected the data. SS, KY, MI, YA, HU, EY, KO, and JS carried out the  
4 statistical analyses and interpreted the data results. SS, KY, MI, and HY wrote the  
5 manuscript. EY, HS, HK, HJ, KK, HY, HO, and KT supervised the project. SS, KY, and  
6 MI contributed equally to this article. All authors read and approved the final manuscript.

7

8 **Funding**

9 Not applicable.

10

11 **Competing interests**

12 Dr. Hisao Ogawa has received remuneration for lectures from AstraZeneca, Bayer Yakuhin,  
13 Ltd., Daiichi Sankyo Co., Ltd., Eisai, Kowa Pharmaceutical Co. Ltd., Takeda Pharmaceutical  
14 Co., Ltd., Teijin Pharma, JSR, Nxera Pharma. Dr. Koichi Kaikita received grants from  
15 Grants-in-Aid for Scientific Research (23K07534) from the Ministry of Education, Culture,  
16 Sports, Science and Technology of Japan; received remuneration for lecture from Bayer  
17 Yakuhin, Ltd., Daiichi-Sankyo Co., Ltd., Novartis Pharma AG., Otsuka Pharmaceutical Co.,  
18 Ltd., Bristol-Myers K.K., and Kowa Pharmaceutical Co. Ltd.; received trust research/joint  
19 research funds from Bayer Yakuhin, Ltd., and Daiichi-Sankyo Co., Ltd.; and received

1 scholarship fund from Abbott Medical Co., Ltd. Dr. Kenichi Tsujita has received  
2 remuneration for lectures from Abbott Medical Co., Ltd, Amgen K.K., Bayer Yakuhin, Ltd.,  
3 Daiichi Sankyo Co., Ltd., Kowa Pharmaceutical Co. Ltd., Nippon Boehringer Ingelheim Co.,  
4 Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co.,Ltd., Pfizer Japan Inc., Takeda  
5 Pharmaceutical Co., Ltd., and TERUMO Co, Ltd.; has received trust research/joint research  
6 funds from Bayer Yakuhin, Ltd., Bristol-Myers K.K., Daiichi Sankyo Co., Ltd., MOCHIDA  
7 PHARMACEUTICAL CO., LTD., Novo Nordisk Pharma Ltd., and PRA Health Sciences.; has  
8 received scholarship fund from Abbott Medical Co., Ltd., ITI Co.,Ltd., Boehringer Ingelheim  
9 Japan, Otsuka Pharmaceutical Co.,Ltd., and Boston Scientific Japan K.K.; has received  
10 Affiliation with Endowed Department from Abbott Japan Co., Ltd., Boston Scientific Japan  
11 K.K., Fides-one, Inc., GM Medical Co., Ltd., ITI Co.,Ltd., Kaneka Medix Co., Ltd., NIPRO  
12 CORPORATION, TERUMO Co, Ltd., Philips Japan Ltd., Getinge Group Japan K.K.,  
13 Orbusneich Medical K. K, Abbott Medical Co., Ltd., BIOTRONIK JAPAN,INC, Boston  
14 Scientific Japan K.K., Fukuda Denshi Co., Ltd., Japan Lifeline Co.,Ltd., Medtoronic Japan  
15 Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., and NIPRO CORPORATION.

16

### 17 **Patient and public involvement**

18 Patients and/or the public were not involved in the design, or conduct, or reporting, or  
19 dissemination plans of this research.

1

2 **Patients consent for publication**

3 Not applicable.

4

5 **Ethics approval**

6 This study was conducted in accordance with the principles contained in the Declaration of

7 Helsinki. The protocol of our study was approved by the ethics committee of the Faculty of

8 Life Sciences, Kumamoto University, and the Japanese Red Cross Kumamoto Hospital Health

9 Care Centre (approval number: 473). We obtained a signed informed consent from each

10 patient and participant. This study is registered at the University Hospital Medical

11 Information Network (UMIN) Clinical Trials Registry (UMIN 000043834). Opt-out

12 materials are available through the website: <https://kumadai-junnai.com/archives/clinical>.

13

14 **Provenance and peer review**

15 Not commissioned; externally peer reviewed.

16

17 **Data availability statement**

18 The data that support the findings of this study are available upon reasonable request.

19



1 **Acknowledgement**

2 We thank Michiyo Saito, MT, at our institution for her excellent technical assistance.

3

4 **ORCID iDs**

5 Satoru Suzuki <https://orcid.org/0000-0001-5545-143X>

6 Masanobu Ishii <https://orcid.org/0000-0003-4137-9136>

7 Yuichiro Arima <https://orcid.org/0000-0002-9840-3347>

8 Eiichiro Yamamoto <https://orcid.org/0000-0002-9072-0348>

9 Kenichi Tsujita <https://orcid.org/0000-0002-4314-259X>

## 1   **References**

- 2   1     Hokimoto S, Kaikita K, Yasuda S, *et al.* JCS/CVIT/JCC 2023 Guideline Focused  
3     Update on Diagnosis and Treatment of Vasospastic Angina (Coronary Spastic Angina)  
4     and Coronary Microvascular Dysfunction. *Circ J* 2023;87:879-936.
- 5   2     Perera D, Berry C, Hoole SP, *et al.* Invasive coronary physiology in patients with  
6     angina and non-obstructive coronary artery disease: a consensus document from the  
7     coronary microvascular dysfunction workstream of the British Heart  
8     Foundation/National Institute for Health Research Partnership. *Heart* 2022;109:88-95.
- 9   3     Suzuki S, Kaikita K, Yamamoto E, *et al.* Role of acetylcholine spasm provocation test  
10    as a pathophysiological assessment in nonobstructive coronary artery disease.  
11    *Cardiovasc Interv Ther* 2021;36:39-51.
- 12  4     Kunadian V, Chieffo A, Camici PG, *et al.* An EAPCI Expert Consensus Document on  
13    Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European  
14    Society of Cardiology Working Group on Coronary Pathophysiology &  
15    Microcirculation Endorsed by Coronary Vasomotor Disorders International Study  
16    Group. *Eur Heart J* 2020;41:3504-20.
- 17  5     Tamis-Holland JE, Jneid H, Reynolds HR, *et al.* Contemporary Diagnosis and  
18    Management of Patients With Myocardial Infarction in the Absence of Obstructive  
19    Coronary Artery Disease: A Scientific Statement From the American Heart Association.  
20    *Circulation* 2019;139:e891-e908.
- 21  6     Shimokawa H, Suda A, Takahashi J, *et al.* Clinical characteristics and prognosis of  
22    patients with microvascular angina: an international and prospective cohort study by  
23    the Coronary Vasomotor Disorders International Study (COVADIS) Group. *Eur Heart*  
24    *J* 2021;42:4592-600.
- 25  7     Ohba K, Sugiyama S, Sumida H, *et al.* Microvascular coronary artery spasm presents

- 1 distinctive clinical features with endothelial dysfunction as nonobstructive coronary  
2 artery disease. *J Am Heart Assoc* 2012;1:e002485.
- 3 8 Mygind ND, Michelsen MM, Pena A, *et al.* Coronary Microvascular Function and  
4 Cardiovascular Risk Factors in Women With Angina Pectoris and No Obstructive  
5 Coronary Artery Disease: The iPOWER Study. *J Am Heart Assoc* 2016;5:e003064.
- 6 9 Pepine CJ, Anderson RD, Sharaf BL, *et al.* Coronary microvascular reactivity to  
7 adenosine predicts adverse outcome in women evaluated for suspected ischemia results  
8 from the National Heart, Lung and Blood Institute WISE (Women's Ischemia  
9 Syndrome Evaluation) study. *J Am Coll Cardiol* 2010;55:2825-32.
- 10 10 Zeiher AM, Schächinger V, Minners J. Long-term cigarette smoking impairs  
11 endothelium-dependent coronary arterial vasodilator function. *Circulation*  
12 1995;92:1094-100.
- 13 11 Chhabra L, Kowlgi NG. Low Incidence of Diabetes Mellitus in Coronary  
14 Microvascular Dysfunction: An Intriguing Association. *JACC Cardiovasc Interv*  
15 2016;9:395-6.
- 16 12 Sara JD, Widmer RJ, Matsuzawa Y, *et al.* Prevalence of Coronary Microvascular  
17 Dysfunction Among Patients With Chest Pain and Nonobstructive Coronary Artery  
18 Disease. *JACC Cardiovasc Interv* 2015;8:1445-53.
- 19 13 Crea F, Montone RA, Rinaldi R. Pathophysiology of Coronary Microvascular  
20 Dysfunction. *Circ J* 2022;86:1319-28.
- 21 14 Ong P, Camici PG, Beltrame JF, *et al.* International standardization of diagnostic  
22 criteria for microvascular angina. *Int J Cardiol* 2018;250:16-20.
- 23 15 Yamanaga K, Tsujita K, Komura N, *et al.* Single-wire pressure and flow velocity  
24 measurement for quantifying microvascular dysfunction in patients with coronary  
25 vasospastic angina. *Am J Physiol Heart Circ Physiol* 2015;308:H478-84.

- 1 16 Kashiwagi A, Kasuga M, Araki E, *et al.* International clinical harmonization of  
2 glycated hemoglobin in Japan: From Japan Diabetes Society to National  
3 Glycohemoglobin Standardization Program values. *J Diabetes Investig* 2012;3:39-40.
- 4 17 Sörensen BM, Houben AJ, Berendschot TT, *et al.* Prediabetes and Type 2 Diabetes Are  
5 Associated With Generalized Microvascular Dysfunction: The Maastricht Study.  
6 *Circulation* 2016;134:1339-52.
- 7 18 Sabanayagam C, Liew G, Tai ES, *et al.* Relationship between glycated haemoglobin  
8 and microvascular complications: is there a natural cut-off point for the diagnosis of  
9 diabetes? *Diabetologia* 2009;52:1279-89.
- 10 19 Furukawa M, Onoue T, Kato K, *et al.* Prediabetes is associated with proteinuria  
11 development but not with glomerular filtration rate decline: A longitudinal  
12 observational study. *Diabet Med* 2021;38:e14607.
- 13 20 Andreotti F, Coluzzi G, Lavorgna A, *et al.* Relation between nitric oxide metabolites  
14 and haemoglobin concentrations in patients with ischaemic heart disease. *Heart*  
15 2007;93:255-7.
- 16 21 Toth PP, Simko RJ, Palli SR, *et al.* The impact of serum lipids on risk for  
17 microangiopathy in patients with type 2 diabetes mellitus. *Cardiovasc Diabetol*  
18 2012;11:109.
- 19 22 Li Z, Huang Q, Sun L, *et al.* Atherogenic Index in Type 2 Diabetes and Its Relationship  
20 with Chronic Microvascular Complications. *Int J Endocrinol* 2018;2018:1765835.
- 21 23 Jansen TPJ, Elias-Smale SE, van den Oord S, *et al.* Sex Differences in Coronary  
22 Function Test Results in Patient With Angina and Nonobstructive Disease. *Front*  
23 *Cardiovasc Med* 2021;8:750071.
- 24 24 Ong P, Athanasiadis A, Borgulya G, *et al.* Clinical usefulness, angiographic  
25 characteristics, and safety evaluation of intracoronary acetylcholine provocation testing

1           among 921 consecutive white patients with unobstructed coronary arteries. *Circulation*  
2           2014;129:1723-30.

3   25    Tsujita K, Yamanaga K, Komura N, *et al.* Impact of left ventricular hypertrophy on  
4           impaired coronary microvascular dysfunction. *Int J Cardiol* 2015;187:411-3.

5   26    Schumann CL, Mathew RC, Dean JL, *et al.* Functional and Economic Impact of  
6           INOCA and Influence of Coronary Microvascular Dysfunction. *JACC Cardiovasc*  
7           *Imaging* 2021;14:1369-79.

8

1 **Legends**

2

3 **Figure 1. Flow chart of patient enrollment**

4 ACh, acetylcholine; CFR, coronary flow reserve.

**Table 1. Clinical Characteristics of MVA Patients and Control Participants**

	All (n =783)	MVA (n =92)	Control (n =691)	p value
Age (years)	63.0±11.1	63.2±12.1	62.9±11.0	0.82
Sex (women) (%)	278 (36%)	53 (58%)	225 (33%)	<0.001
BMI (kg/m <sup>2</sup> )	23.2±3.1	23.3±3.7	23.1±3.0	0.55
Current smoking (%)	110 (14%)	16 (17%)	94 (14%)	0.34
HT (%)	307 (39%)	45 (49%)	262 (38%)	0.055
DM (%)	119 (15%)	19 (21%)	100 (14%)	0.16
DLP (%)	423 (54%)	40 (43%)	383 (55%)	0.034
eGFR (mL/min/1.73m <sup>2</sup> )	73±14	74±18	73±13	0.41
Uric acid (µmol/L)	324±83	318±91	325±82	0.47
FPG (mmol/L)	5.6±1.0	5.4±1.7	5.6±0.9	0.12
HbA1c (mmol/mol)	38±9	44±11	37±8	<0.001
HbA1c excluding DM patients (mmol/mol)	35±4	39±4	34±3	<0.001
LDL-C (mmol/L)	3.1±0.7	3.0±0.9	3.1±0.7	0.050
HDL-C (mmol/L)	1.7±0.4	1.5±0.4	1.7±0.4	<0.001
TG (mmol/L)	1.1 (0.8-1.5)	1.2 (0.9-1.6)	1.1 (0.8-1.5)	0.061
CRP (mg/L)	0.50 (0.30-1.00)	0.65(0.30-1.55)	0.50(0.30-1.00)	0.006
WBC (×10 <sup>9</sup> /L)	5.4±1.5	5.7±1.6	5.4±1.5	0.062
RBC (×10 <sup>12</sup> /L)	4.59±0.42	4.29±0.44	4.63±0.40	<0.001
Hgb (g/L)	144±14	132±14	146±13	<0.001
Platelets (×10 <sup>9</sup> /L)	210±49	213±58	210±47	0.54
Proteinuria (%)	16/656 (2%)	7/58 (12%)	9/598 (2%)	<0.001
CFR	---	2.4±1.0 (n =55)	no data	
CFR ≥2.0 (%)	---	35/55 (64%)	no data	
<u>Medications (on admission)</u>				
ACE-I or ARB (%)	---	28 (30%)	no data	---
CCB (%)	---	46 (50%)	no data	---
Nitrate (%)	---	18 (20%)	no data	---
Beta-blocker (%)	---	21 (23%)	no data	---
Statin (%)	---	27 (29%)	no data	---

Data are number of patients (%), means ± standard deviation (SD), and medians (interquartile

range). MVA, microvascular angina; BMI, body mass index; HT, hypertension; DM, diabetes mellitus; DLP, dyslipidaemia; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; CRP, C-reactive protein; WBC, white blood cell; RBC, red blood cell; Hgb, haemoglobin; CFR, coronary flow reserve; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker.



**Table 2. Clinical Characteristics of MVA Patients and Control Participants in Men and Women**

	Men (n =505)			Women (n =278)		
	MVA (n =39)	Control (n =466)	p value	MVA (n =53)	Control (n =225)	p value
Age (years)	61.4±13.9	61.5±11.8	0.95	64.6±10.6	65.9±8.3	0.32
BMI (kg/m <sup>2</sup> )	23.6±3.5	23.5±2.8	0.87	23.2±3.9	22.4±3.3	0.12
Current smoking (%)	10 (26%)	91 (20%)	0.40	6 (11%)	3 (1%)	0.002
HT (%)	21 (54%)	184 (39%)	0.090	24 (45%)	78 (35%)	0.16
DM (%)	10 (26%)	81 (17%)	0.20	9 (17%)	19 (8%)	0.076
DLP (%)	16 (41%)	249 (53%)	0.18	24 (45%)	134 (60%)	0.066
eGFR (mL/min/1.73m <sup>2</sup> )	73±19	72±13	0.50	74±17	75±13	0.94
Uric acid (µmol/L)	367±90	351±78	0.23	280±73	270±60	0.21
FPG (mmol/L)	5.6±1.5	5.7±1.0	0.67	5.3±1.1	5.4±0.8	0.35
HbA1c (mmol/mol)	43±11	38±9	0.002	44±11	36±7	<0.001
HbA1c excluding DM patients (mmol/mol)	37±4	34±3	<0.001	40±4	34±3	<0.001
LDL-C (mmol/L)	2.9±1.0	3.1±0.7	0.067	3.1±0.8	3.2±0.6	0.19
HDL-C (mmol/L)	1.4±0.4	1.6±0.4	<0.001	1.5±0.5	1.9±0.5	<0.001
TG (mmol/L)	1.3(1.0-1.8)	1.1(0.8-1.6)	0.082	1.2(0.9-1.5)	0.9(0.7-1.3)	0.032
CRP (mg/L)	0.60(0.30-1.20)	0.50(0.30-1.00)	0.098	0.80(0.30-1.90)	0.50(0.30-1.00)	0.024
WBC (×10 <sup>9</sup> /L)	6.0±1.7	5.6±1.5	0.10	5.5±1.5	5.0±1.2	0.022
RBC (×10 <sup>12</sup> /L)	4.47±0.32	4.74±0.40	<0.001	4.16±0.48	4.40±0.31	<0.001
Hgb (g/L)	140±14	151±11	<0.001	126±11	135±9	<0.001
Platelets (×10 <sup>9</sup> /L)	203±58	206±4.8	0.72	221±57	217±45	0.60
Proteinuria (%)	3/21 (14%)	7/392 (2%)	0.011	4/37 (11%)	2/206 (1%)	0.006
CFR	1.9±0.9 (n =17)	no data	---	2.7±0.9 (n =38)	no data	---
CFR ≥2.0 (%)	6/17 (35%)	no data		29/38 (76%)	no data	
<u>Medications (on admission)</u>						
ACE-I or ARB (%)	18 (46%)	no data	---	10 (19%)	no data	---
CCB (%)	17 (44%)	no data	---	29 (55%)	no data	---
Nitrate (%)	9 (23%)	no data	---	9 (17%)	no data	---
Beta-blocker (%)	16 (41%)	no data	---	5 (9%)	no data	---
Statin (%)	10 (25%)	no data	---	17 (32%)	no data	---

Data are number of patients (%), means  $\pm$  standard deviation (SD), and medians (interquartile range). MVA, microvascular angina; BMI, body mass index; HT, hypertension; DM, diabetes mellitus; DLP, dyslipidaemia; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; CRP, C-reactive protein; WBC, white blood cell; RBC, red blood cell; Hgb, haemoglobin; CFR, coronary flow reserve; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker.

**Table 3. Univariate and Multivariate Logistic Regression Analysis for MVA**

	Univariate		Multivariate	
	Odds Ratio (95%CI)	p value	Odds Ratio (95%CI)	p value
Sex (women)	2.82 (1.81-4.39)	<0.001	1.64 (0.86-3.14)	0.13
BMI (per 1 kg/m <sup>2</sup> )	1.02 (0.95-1.10)	0.55		
Current smoking	1.34 (0.75-2.39)	0.33		
HT	1.57 (1.01-2.43)	0.044	1.29 (0.73-2.29)	0.38
DM	1.54 (0.89-2.66)	0.12		
DLP	0.62 (0.40-0.96)	0.032	not selected *	
eGFR (per 1 mL/min/1.73m <sup>2</sup> )	1.01 (0.99-1.02)	0.41		
Uric acid (per 1 μmol/L)	1.00 (1.00-1.00)	0.46		
FPG (per 1 mmol/L)	0.80 (0.60-1.06)	0.12		
HbA1c (per 1 mmol/mol)	1.07 (1.04-1.10)	<0.001	1.07 (1.04-1.10)	<0.001
LDL-C (per 1 mmol/L)	0.73 (0.53-1.00)	0.051		
HDL-C (per 1 mmol/L)	0.21 (0.11-0.39)	<0.001	0.13 (0.06-0.29)	<0.001
TG (per 1 mmol/L)	1.09 (0.85-1.39)	0.50		
CRP (per 1 mg/L)	1.06 (0.98-1.15)	0.13		
WBC (per 1×10 <sup>9</sup> /L)	1.14 (0.99-1.31)	0.063		
Hgb (per 10×g/L)	0.46 (0.39-0.56)	<0.001	0.56 (0.44-0.72)	<0.001
Platelets (per 10×10 <sup>9</sup> /L)	1.01 (0.97-1.06)	0.54		
Proteinuria	8.98 (3.21-25.1)	<0.001	not selected **	

\* We did not evaluate DLP in the multivariate logistic regression analysis because the correlation between DLP and HDL-C level was strong. \*\* We did not evaluate 'Proteinuria' in the multivariate logistic regression analysis because the number of patients with proteinuria was low (regarding these contents, see also Statistical analyses in Methods).

MVA, microvascular angina; CI, confidence interval; BMI, body mass index; HT, hypertension; DM, diabetes mellitus; DLP, dyslipidaemia; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; CRP, C-reactive protein; WBC, white blood cell; Hgb, haemoglobin.

**Table 4. Univariate and Multivariate Logistic Regression Analysis for MVA in Men**

	Univariate		Multivariate	
	Odds Ratio (95%CI)	p value	Odds Ratio (95%CI)	p value
BMI (per 1 kg/m <sup>2</sup> )	1.01 (0.90-1.14)	0.87		
Current smoking	1.42 (0.67-3.02)	0.36		
HT	1.79 (0.93-3.45)	0.083		
DM	1.64 (0.77-3.50)	0.20		
DLP	0.61 (0.31-1.18)	0.14		
eGFR (per 1 mL/min/1.73m <sup>2</sup> )	1.01 (0.99-1.03)	0.50		
Uric acid (per 1 µmol/L)	1.00 (1.00-1.00)	0.23		
FPG (per 1 mmol/L)	0.93 (0.65-1.32)	0.67		
HbA1c (per 1 mmol/mol)	1.05 (1.02-1.08)	0.004	1.04 (1.00-1.08)	0.034
LDL-C (per 1 mmol/L)	0.65 (0.41-1.03)	0.068		
HDL-C (per 1 mmol/L)	0.11 (0.04-0.32)	<0.001	0.10 (0.03-0.34)	<0.001
TG (per 1 mmol/L)	1.28 (0.92-1.78)	0.15		
CRP (per 1 mg/L)	1.05 (0.95-1.15)	0.34		
WBC (per 1×10 <sup>9</sup> /L)	1.18 (0.97-1.42)	0.10		
Hgb (per 10×g/L)	0.51 (0.39-0.66)	<0.001	0.64 (0.48-0.87)	0.004
Platelets (per 10×10 <sup>9</sup> /L)	1.00 (0.92-1.06)	0.72		
Proteinuria	9.17 (2.19-34.4)	0.002	not selected *	

\* We did not evaluate ‘Proteinuria’ in the multivariate logistic regression analysis because the number of patients with proteinuria was low (regarding the content, see also Statistical analyses in Methods).

MVA, microvascular angina; CI, confidence interval; BMI, body mass index; HT, hypertension; DM, diabetes mellitus; DLP, dyslipidaemia; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; CRP, C-reactive protein; WBC, white blood cell; Hgb, haemoglobin.

**Table 5. Univariate and Multivariate Logistic Regression Analysis for MVA in Women**

	Univariate		Multivariate	
	Odds Ratio (95%CI)	p value	Odds Ratio (95%CI)	p value
BMI (per 1 kg/m <sup>2</sup> )	1.07 (0.98-1.16)	0.12		
Current smoking	9.45 (2.28-39.1)	0.002	not selected *	
HT	1.56 (0.85-2.86)	0.15		
DM	2.22 (0.94-5.23)	0.069		
DLP	0.56 (0.31-1.03)	0.061		
eGFR (per 1 mL/min/1.73m <sup>2</sup> )	1.00 (0.98-1.02)	0.94		
Uric acid (per 1 μmol/L)	1.00 (1.00-1.01)	0.21		
FPG (per 1 mmol/L)	0.87 (0.53-1.25)	0.35		
HbA1c (per 1 mmol/mol)	1.12 (1.07-1.18)	<0.001	1.09 (1.04-1.15)	0.001
LDL-C (per 1 mmol/L)	0.74 (0.46-1.17)	0.19		
HDL-C (per 1 mmol/L)	0.12 (0.05-0.29)	<0.001	0.65 (0.49-0.86)	0.003
TG (per 1 mmol/L)	1.09 (0.77-1.55)	0.63		
CRP (per 1 mg/L)	1.23 (1.01-1.50)	0.042	0.25 (0.01-10.3)	0.47
WBC (per 1×10 <sup>9</sup> /L)	1.30 (1.04-1.62)	0.024	1.50 (1.03-2.20)	0.037
Hgb (per 10×g/L)	0.39 (0.28-0.55)	<0.001	0.41 (0.25-0.65)	<0.001
Platelets (per 10×10 <sup>9</sup> /L)	1.02 (0.96-1.08)	0.60		
Proteinuria	12.4 (2.18-70.2)	0.005	not selected *	

\* We did not evaluate ‘current smoking’ and ‘proteinuria’ in the multivariate logistic regression analysis because the numbers of patients with current smoking or proteinuria were low (regarding these contents, see also Statistical analyses in Methods).

MVA, microvascular angina; CI, confidence interval; BMI, body mass index; HT, hypertension; DM, diabetes mellitus; DLP, dyslipidaemia; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; CRP, C-reactive protein; WBC, white blood cell; Hgb, haemoglobin.

**Table 6. Erythrocyte Indices of MVA in Men and Women**

	Men (n =505)			Women (n =278)		
	MVA (n =39)	Control (n =466)	p value	MVA (n =53)	Control (n =225)	p value
RBC ( $\times 10^{12}/L$ )	4.47 $\pm$ 0.32	4.74 $\pm$ 0.40	<0.001	4.16 $\pm$ 0.48	4.40 $\pm$ 0.31	<0.001
Haematocrit (L/L)	0.41 $\pm$ 0.04	0.45 $\pm$ 0.03	<0.001	0.38 $\pm$ 0.03	0.41 $\pm$ 0.03	<0.001
Hgb (g/L)	140 $\pm$ 14	151 $\pm$ 11	<0.001	126 $\pm$ 11	135 $\pm$ 9	<0.001
MCV (fL)	91.8 $\pm$ 4.0	95.1 $\pm$ 3.9	<0.001	92.0 $\pm$ 4.0	93.8 $\pm$ 3.9	<0.001
Serum iron ( $\mu$ mol/L)	20 $\pm$ 12	21 $\pm$ 7	0.25	16 $\pm$ 6	20 $\pm$ 6	<0.001
Ferritin ( $\mu$ g/L)	168 $\pm$ 121	139 $\pm$ 108	0.26	83 $\pm$ 80	75 $\pm$ 55	0.62

Data are number of patients (%), means  $\pm$  standard deviation (SD). MVA, microvascular angina; Hgb, haemoglobin; MCV, mean corpuscular volume.

1 **Table 7. Clinical Characteristics of 55 MVA Patients Stratified into Those with a CFR**  
 2 **<2.0 and Those with a CFR ≥2.0**

3

	<b>CFR &lt;2.0</b> (n=20)	<b>CFR ≥2.0</b> (n =35)	p value
Age (years)	64.6±12.9	62.3±11.8	0.52
Sex (women), (%)	9 (45%)	29 (83%)	0.006
BMI (kg/m <sup>2</sup> )	23.3±4.1	24.0±4.2	0.51
Current smoking (%)	1 (5%)	6 (17%)	0.40
HT (%)	7 (35%)	20 (57%)	0.16
DM (%)	3 (15%)	7 (20%)	0.73
DLP (%)	8 (40%)	18 (51%)	0.56
eGFR (mL/min/1.73m <sup>2</sup> )	71±15	73±15	0.72
Uric acid (μmol/L)	297±102	308±67	0.62
FPG (mmol/L)	5.6±1.1	5.3±1.2	0.47
HbA1c (mmol/mol)	42±8	44±12	0.46
HbA1c excluding DM patients (mmol/mol)	39±4	40±4	0.55
LDL-C (mmol/L)	2.8±0.7	3.0±0.8	0.49
HDL-C (mmol/L)	1.5±0.4	1.5±0.5	0.93
TG (mmol/L)	1.2 (0.8-1.6)	1.2 (0.9-1.6)	0.81
CRP (mg/L)	0.30 (0.28-1.33)	0.80 (0.30-1.50)	0.59
WBC (×10 <sup>9</sup> /L)	6.1±2.2	5.4±1.2	0.11
RBC (×10 <sup>12</sup> /L)	4.31 ±0.41	4.32±0.44	0.94
Hgb (g/L)	135±13	133±16	0.62
Platelets (×10 <sup>9</sup> /L)	200±65	225±64	0.17
Proteinuria (%)	1/12 (8%)	3/27 (11%)	1.00
<u>Medications (on admission)</u>			
ACE-I or ARB (%)	8 (40%)	10 (29%)	0.55
CCB (%)	10 (50%)	24 (69%)	0.25
Nitrate (%)	5 (25%)	8 (23%)	1.00
Beta-blocker (%)	6 (30%)	6 (17%)	0.32
Statin (%)	9 (45%)	11 (31%)	0.39

4

5 Data are number of patients (%), means ± standard deviation (SD), and medians (interquartile

1 range). CFR, coronary flow reserve; MVA, microvascular angina; BMI, body mass index;  
2 HT, hypertension; DM, diabetes mellitus; DLP, dyslipidaemia; eGFR, estimated glomerular  
3 filtration rate; FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; LDL-C, low-density  
4 lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; CRP,  
5 C-reactive protein; WBC, white blood cell; RBC, red blood cell; Hgb, haemoglobin; ACE-I,  
6 angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium  
7 channel blocker.

8



**Figure 1**

